Trials / Completed
CompletedNCT00038974
Hepatitis C Antiviral Resistance in African-Americans
Study of Viral Resistance to Antiviral Therapy of Chronic Hepatitis C (Virahep-C)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 401 (actual)
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · NIH
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to test the hypothesis that African-Americans respond less well to combination pegylated interferon and ribavirin therapy than Caucasian-Americans who have chronic hepatitis C genotype 1 and who were not previously treated with either interferon or ribavirin. Reasons for differences in response, regardless of race, will be studied.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | peginterferon alfa-2a | |
| DRUG | Ribavirin |
Timeline
- Start date
- 2002-08-01
- Primary completion
- 2004-12-01
- Completion
- 2005-11-01
- First posted
- 2002-06-10
- Last updated
- 2017-08-03
Locations
8 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT00038974. Inclusion in this directory is not an endorsement.